Skip to main content

Table 1 Patients’ characteristics

From: Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy

 

Control (n = 30)

Non-LVH (n = 29)

LVH (n = 30)

F

P

Gender (male/female)

16/14

13/16

21/9

  

Age (years)

58.53 ± 10.17

59.07 ± 11.79

58.03 ± 14.93

0.28

0.755

LVM (male)

133.02 ± 30.97

145.19 ± 25.43*

219.45 ± 29.23*#

30.84

 < 0.001

LVM (female)

105.40 ± 16.28

131.62 ± 23.18*

209.29 ± 27.38*#

37.13

 < 0.001

LVMI

74.01 ± 11.87

74.12 ± 13.02

115.95 ± 9.98*#

85.59

 < 0.001

SBP

123.75 ± 11.08

146.46 ± 27.63*

155.57 ± 11.65*

4.55

0.015

DBP

73.50 ± 5.06

85.42 ± 9.42*

90.46 ± 10.23*

6.09

0.004

BMI (kg/m2)

23.13 ± 1.23

24.62 ± 2.21

24.51 ± 4.06

0.23

0.801

TC (mmol/L)

4.17 ± 0.79

4.69 ± 0.91

4.79 ± 1.03

0.89

0.416

LDL-C (mmol/L)

1.29 ± 0.19

1.39 ± 0.34

1.47 ± 0.54

1.24

0.296

HDL-C (mmol/L)

2.48 ± 0.31

2.83 ± 0.76

2.55 ± 0.74

1.21

0.304

TG (mmol/L)

1.79 ± 1.43

1.89 ± 1.24

1.84 ± 1.01

0.01

0.987

Hs-CRP (mg/L)

11.50 ± 1.29

12.42 ± 3.09*

14.12 ± 4.32*#

2.01

0.143

Hcy (umol/L)

1.43 ± 0.65

1.37 ± 0.98

2.87 ± 1.87*

7.82

0.001

β-2MG (mg/L)

1.85 ± 0.47

1.98 ± 0.53

2.70 ± 0.72*

10.69

< 0.001

  1. *P < 0.05 versus control, #P < 0.05 versus non-LVH group